2026 Program

At BIO 2026, where science meets real-world impact, you can access more than 135 sessions across 18 focus areas with discussions from leading biotechnology companies, investors, service providers, government officials, regulators and patient advocates.

Accelerate your career growth by adding a Professional Development Course to your BIO 2026 registration. Learn more.

Loading
1:00 PM (PT)
  1. Company Presentation Session
    Company Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...
    Company Presentation Session
  2. This session brings together leaders from pharma, AI technology, life sciences platforms, CROs, and specialized biotech AI to cut through the noise and examine how artificial intelligence is deliverin ...
    Breakout Session 28ABCDE
  3. Within the Asia Pacific Region, Google Health and Health2Sync have partnered with Taiwan's National Health Insurance Administration and AI to stratify diabetes patients at risk of complications and th ...
    Breakout Session 29AB
  4. The healthcare ecosystem is experiencing an unprecedented transformation fueled by scientific, technological, geopolitical, economic, and demographic changes. Whilst breakthrough innovations are shapi ...
    Breakout Session 29C
  5. A longstanding priority for both Congress and FDA, there has been a significant evolution in recent years in the ways in which patients’ experiences and preferences have been incorporated into the dru ...
    Breakout Session 24BC
  6. Real world data (RWD) are increasingly relied upon to inform drug policy decisions at both the state and federal levels. For example, state Prescription Drug Affordability Boards (PDABs) are using all ...
    Breakout Session 26AB
2:15 PM (PT)
  1. The United States is making unprecedented investments to reshore biomanufacturing, strengthen supply chains, and enhance national security. As new facilities rise across the country, a critical questi ...
    Breakout Session 30DE
  2. The financing and partnering environment for biotech has shifted significantly in recent years. Investors and partners have increasingly prioritized tangible, de-risked assets that offer compelling th ...
    Breakout Session 25ABC
  3. HBO Max’s “The Last of Us" captivated audiences with its gripping portrayal of a post-apocalyptic world ravaged by a fungal infection. While fictional, the threat posed by fungal pathogens is real. Fu ...
    Breakout Session 31C
  4. For the first time in history, a patient has survived more than eight months following a gene-edited pig organ transplant, marking a pivotal moment as xenotransplantation moves from experimental promi ...
    Breakout Session 24BC
  5. Biomarker legislation is reshaping insurance and diagnostics policy across many US states, with more than 20 currently mandating coverage for biomarker testing under certain conditions. However, trans ...
    Breakout Session 26AB
3:30 PM (PT)
  1. This session will explore how quantum computing is poised to redefine the frontiers of drug discovery by solving complex molecular and optimization problems that exceed the limits of classical computi ...
    Breakout Session 28ABCDE
  2. Clinical trials for large-population diseases face persistent challenges and remain the most complex and resource-intensive steps in drug development. Patient recruitment often lags, administrative bo ...
    Breakout Session 29AB
  3. This session will feature a Fireside Chat between the former CEO of Capstan Therapeutics, as they share firsthand experience leading Capstan through one of the marquee M&A deals of 2025, a $2B+ acquis ...
    Breakout Session 30DE
  4. The China-US relationship will have a huge role in shaping the future of global biotech. Yet, this relationship is increasingly defined by both interdependence and tension — with science, supply chain ...
    Breakout Session 29C
  5. More than 10 million Americans live with osteoporosis. For decades, proving whether a new osteoporosis drug worked meant running massive clinical trials that followed thousands of people for 10–12 yea ...
    Breakout Session 30ABC
  6. There’s no question that drug development is a risky endeavor with scientific, clinical, and commercial risk. Patients and society value advances in science that help people get well, stay healthy, an ...
    Breakout Session 26AB
9:00 AM (PT)
10:00 AM (PT)
  1. BioProcess International Theatre BioProcess Theatre
  2. BioProcess Session BioProcess Theatre
10:15 AM (PT)
  1. • Contracting and Pricing • Demand Forecasting • Gross-to-Net • Pre-/Post- Deal Analysis • Accruals Management • Revenue Management
    BioProcess Session BioProcess Theatre
10:30 AM (PT)
  1. Company Presentation Session
    Company Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...
    Company Presentation Session
11:00 AM (PT)
  1. The next evolution of AI in biopharma is already here - systems designed not just to analyze data but to make decisions. These “agentic AI” models can set goals, adapt strategies, and generate hypothe ...
    Breakout Session 31AB
  2. This session will explore the critical journey of translating a scientific concept into a viable CNS therapeutic. Industry leaders will discuss the primary challenges and emerging solutions in neurosc ...
    Breakout Session 24BC
  3. As major patent expirations loom, pricing pressures intensify and R&D productivity comes under strain, large pharmaceutical companies are accelerating dealmaking to fill therapeutic and clinical-stage ...
    Breakout Session 30ABC
  4. Messenger RNA (mRNA) medicines are increasingly recognized for their transformative power to improve patient health, as well as a strategic asset with implications for national and global security. Th ...
    Breakout Session 29C
  5. Healthcare providers are often faced with the same set of challenges when diagnosing women with Alzheimer’s – debunking the stigma that has shaped the Alzheimer’s narrative for women and their familie ...
    Breakout Session 31C
  6. Europe is actively working to improve the clinical research environment, with particular emphasis on supporting biotechnology innovation and adapting to evolving scientific and societal needs. As new ...
    Breakout Session 23BC
  7. The life sciences industry is built on innovation and driven by purpose. As competing for talent and earning public trust become critical business drivers, leading life sciences companies are investin ...
    Breakout Session 26AB
11:45 AM (PT)
  1. BioProcess Session BioProcess Theatre
12:00 PM (PT)
  1. CDMO Capacity and Client Partnership Panel • How do you ensure your capacity planning aligns with actual client requirements rather than assumptions? • How do you balance multiple clients competing fo ...
    BioProcess Session BioProcess Theatre
12:15 PM (PT)
  1. Super Session
    The biopharma industry has reached a critical inflection point. As it enters new scientific frontiers, it is simultaneously faced with increased budgetary pressures, looming patent cliffs, and—in the ...
    Super Session 28ABCDE
    Sponsored by Genentech
1:00 PM (PT)
  1. BioProcess Session BioProcess Theatre
1:45 PM (PT)
  1. AI is redefining what’s possible across industries, and nowhere is the opportunity greater than in life sciences. But unlocking its full power requires more than algorithms — it demands bold new ways ...
    Breakout Session 31AB
  2. Macroeconomic challenges that have hindered biotech IPO activity are subsiding and capital markets are expected to improve later in 2026, especially for early-stage biotech companies. Increased M&A ac ...
    Breakout Session 25ABC
  3. This session will explore how pharma/biotech companies achieve pipeline diversity through portfolio strategy, strategic collaborations, and scientific rigor. The conversation will examine the processe ...
    Breakout Session 30ABC
2:40 PM (PT)
  1. BioProcess International Theatre BioProcess Theatre
3:00 PM (PT)
  1. AI is becoming ubiquitous in biopharma, but no company can unlock its full potential alone. As the industry shifts from "tell me" to "show me," the pressure is on to move beyond the hype and use AI to ...
    Breakout Session 30DE
    Sponsored by Genentech
  2. AI-enabled discovery and multimodal, human-centric datasets are reshaping how biopharma and digital health companies differentiate, partner, and scale. Rather than focusing on capital trends, this ses ...
    Breakout Session 31AB
  3. As life sciences innovation becomes increasingly global, many emerging biotech ecosystems continue to face barriers to accessing the capital, infrastructure, and networks that define established hubs ...
    Breakout Session 30ABC
  4. This session explores how patient preference studies (PPS) are transforming regulatory strategies in drug development, aligning with the upcoming ICH E22 guideline - the first international guideline ...
    Breakout Session 32AB
  5. Kickstart your journey in biotechnology by exploring the industry’s vast landscape and discovering where your skills and interests can make an impact. Experts will provide an overview of biotech acros ...
    Breakout Session 29AB
3:55 PM (PT)
  1. What manufacturing innovations have delivered the most significant cost reductions while maintaining product quality in your biologics operations? How are you balancing the capital investment required ...
    BioProcess Session BioProcess Theatre
4:15 PM (PT)
  1. Cancer immunotherapy has transformed oncology, yet many patients still don't respond or develop resistance to these treatments. Meanwhile, AI has generated unprecedented libraries of potential targets ...
    Breakout Session 31AB
  2. For years, therapeutic development for Alzheimer’s and other neurodegenerative diseases has focused on the pathologies within the brain such as, in the case of Alzheimer’s, amyloid plaques and tau tan ...
    Breakout Session 24BC
  3. With federal agencies commitments being uncertain and wavering, many researchers as well as emerging drug and device developers are struggling to find funding or to continue projects. At the same time ...
    Breakout Session 30ABC
  4. The metabolic disease treatment landscape is transforming rapidly. While GLP-1 receptor agonists have demonstrated remarkable efficacy, addressing the full scope of metabolic dysfunction requires ther ...
    Breakout Session 32AB
  5. We are living in a golden age of biopharmaceutical innovation. Yet, too often, patients face barriers between them and the appropriate treatment they need across various cost-shifting programs. Payers ...
    Breakout Session 29C
  6. As we approach 50 years of biotechnology innovation, a generation of female leaders are reshaping the industry at some of the most influential companies in biopharma, including as CEOs of Vertex and A ...
    Breakout Session 26AB
9:30 AM (PT)
10:30 AM (PT)
  1. Company Presentation Session
    Company Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...
    Company Presentation Session
11:00 AM (PT)
  1. As the global biotech ecosystem becomes increasingly interconnected, in-licensing has evolved into a core growth engine, with US–Asia deal-making and NewCo formation continuing to accelerate as compan ...
    Breakout Session 30ABC
  2. As diagnostics and precision medicine continue to advance, companies developing novel diagnostic technologies, analytical tools, and data-enabled testing solutions are reshaping how disease is detecte ...
    Breakout Session 26AB
  3. The role of vaccines in preventing and eradicating numerous infectious diseases is unparalleled; however, the past year has presented some new challenges for the industry, calling into question the sc ...
    Breakout Session 29C
  4. This session is designed to provide students with the guidance and connections needed to enter the world of biotechnology after receiving their degree. Panelists will share their personal career journ ...
    Breakout Session 29AB
1:40 PM (PT)
1:45 PM (PT)
  1. Although artificial intelligence (AI) has existed for decades, recent advances in computational power, data availability, and machine learning models have significantly accelerated its development and ...
    Breakout Session 30DE
  2. For centuries, nature, and particularly the innate immune system, has encoded powerful mechanisms for disease control and repair. Today, artificial intelligence (AI) is reshaping drug discovery by rev ...
    Breakout Session 31AB
  3. In recent years, a confluence of global economic, market, and policy shifts have led to the abandonment of more than 1,000 promising treatments in development for rare diseases - many of which deliver ...
    Breakout Session 25ABC
  4. This session will explore ARPA-H’s unique SBIR/STTR funding opportunities and the distinctive commercialization support designed to propel breakthrough companies forward. Attendees will hear firsthand ...
    Breakout Session 30ABC
  5. Both Secretary Kennedy and Commissioner Makary have signaled that there will be a new era of “radical transparency” at the Food and Drug Administration (FDA). Regulatory transparency is generally desi ...
    Breakout Session 29C
  6. Oncology continues to be the leading therapeutic area across the biopharma industry by almost all measures, including global drug sales, number of pipeline programs, venture capital dollar deployment, ...
    Breakout Session 24BC
2:30 PM (PT)
  1. As biopharmaceutical pipelines grow increasingly diverse — encompassing monoclonal antibodies, recombinant proteins, gene therapies, cell therapies, and other novel modalities — the pressure to stream ...
    BioProcess Session BioProcess Theatre
3:00 PM (PT)
  1. Until recently, drug discovery has been limited by fundamental practical constraints such as the range of proteins that exist in nature or the availability of samples, time, and funding for experiment ...
    Breakout Session 31AB
  2. Biomanufacturing is at an inflection point. From the outside‑in, macro forces - significant near‑shoring investments over the next 3–5 years, costing pressures, and the need for regional, resilient su ...
    Breakout Session 32AB
  3. This panel discussion addresses a critical paradox in biotechnology investment - while female-founded biotech’s demonstrate superior returns, they receive less than 3% of venture funding. This session ...
    Breakout Session 30ABC
  4. Inherited Retinal Diseases (IRDs) were once considered untreatable, leaving patients and families facing the certainty of progressive vision loss. Today, advances in gene therapy are changing that rea ...
    Breakout Session 23BC
  5. Since the first drugs were selected for “negotiation,” the Inflation Reduction Act (IRA) has been the target of litigation. Two strains of litigation emerged, with one focusing on the constitutionalit ...
    Breakout Session 26AB
4:15 PM (PT)
  1. Death of expertise in the dawn of AI has been vastly overreported with no sign of its ability to displace creative and disciplined drug discovery teams. Citing Bernstein Research, the Financial Times ...
    Breakout Session 30DE
  2. Back by popular demand, this high-impact session returns to BIO and will guide health and science executives through a proprietary framework developed by LaVoieHealthScience: The LHS Fifteen-Slide Pre ...
    Breakout Session 30ABC
  3. The FDA’s new guidance supporting non-animal testing methods is reshaping preclinical drug development, creating unprecedented opportunities for biotech innovation. This session brings together biotec ...
    Breakout Session 29C
  4. The advances in technology over the past decade have yielded a broad range of biologics for cancer, each with unique attributes. This is great news for patients to have so many tools in the toolkit, b ...
    Breakout Session 24BC
  5. Enacted in 1992, the Prescription Drug User Fee Act (PDUFA) establishes how regulated industry fees support the human drug review program at the Food and Drug Administration (FDA) and associated Agenc ...
    Breakout Session 29AB
9:00 AM (PT)
  1. Novel manufacturing technologies can help rapidly scale manufacturing capabilities, increase supply chain resilience, bring manufacturing closer to the patient, and support greener manufacturing. On a ...
    Breakout Session 23BC
  2. In an increasingly selective capital environment, a handful of biotech CEOs have managed to defy the odds—closing $100 million-plus financing rounds that fueled major growth, platform expansion, and p ...
    Breakout Session 25ABC
  3. The biopharmaceutical industry faces persistent misinformation campaigns targeting patent practices, with myths about patent thickets, evergreening, and excessive patent filings driving misguided poli ...
    Breakout Session 29C
  4. Colorado’s life sciences community is relentlessly focused on patients. In this interactive panel, Colorado BioScience Association President & CEO along with the other panelists, will share real-world ...
    Breakout Session 26AB
10:00 AM (PT)
  1. Company Presentation Session
    Company Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...
    Company Presentation Session
10:15 AM (PT)
  1. Cell and gene therapies have become invaluable modalities in the medicine toolkit. Following recent safety concerns with AAV vector technology, experts will look increasingly toward new vectors and de ...
    Breakout Session 23BC
  2. Antibody–drug conjugates (ADCs) reshaped cancer treatment by combining the precision of targeted antibodies with the potency of cytotoxic therapies, but as the field matures, the focus is shifting tow ...
    Breakout Session 24BC
  3. The path from academic discovery to patient impact has never been more complex. Federal funding shifts, market turbulence, and evolving expectations for commercialization are challenging traditional m ...
    Breakout Session 29AB

white squarewhite

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS

Loading